Drugs in Treating Urinary Schistosomiasis
Urinary schistosomiasis caused by trematodes of the genus Schistosoma known as Schistosoma haematobium. Schistosoma haematobium, also known to be “urinary blood fluke” that inhabits and multiplies eggs in the small venules of the perivesical and portal systems. Urinary schistosomiasis is endemic in 53 countries in Africa and the Middle East. A cholinesterase inhibitor Metrifonate is another selective treatment for SH; it has good efficacy and safety properties. Although it is economic, causes low recurrence rates. Metrifonate is that a prophylactic dose which is needed within two years to guard against recurrence. Niridazole is also highly effective for treating schistosomiasis, and a single dose of niridazole daily has a high cure rate.
- In vitro studies
- Albendazole Treatment
- Egg Reduction Rate
Related Conference of Drugs in Treating Urinary Schistosomiasis
11th World Congress and Exhibition on Antibiotics and Antibiotic Resistance
5th International conference on Vaccines, Vaccination and Immunization
Drugs in Treating Urinary Schistosomiasis Conference Speakers
Recommended Sessions
Related Journals
Are you interested in
- Antibiotic Prophylaxis - Antibiotics 2024 (UK)
- Antibiotic Resistance: Opportunities and Challenges - Antibiotics 2024 (UK)
- Antibiotic-resistant Bacterial infections - Antibiotics 2024 (UK)
- Antibiotics - Antibiotics 2024 (UK)
- Antibiotics for Various Diseases and Infections - Antibiotics 2024 (UK)
- Antibiotics: In Pregnancy and Lactation - Antibiotics 2024 (UK)
- Antimicrobial Peptides - Antibiotics 2024 (UK)
- Antimicrobial Therapy - Antibiotics 2024 (UK)
- Cancer Immunology and Immunotherapy - IMMUNOLOGY 2024 (Spain)
- Cell & Plant Biology - IMMUNOLOGY 2024 (Spain)
- Cell Biology - IMMUNOLOGY 2024 (Spain)
- CELL, ANIMAL & PLANT BIOLOGY - IMMUNOLOGY 2024 (Spain)
- Clinical Immunology & Current & Future Research - IMMUNOLOGY 2024 (Spain)
- Clinical Trials of Antibiotics - Antibiotics 2024 (UK)
- Current research in antibiotic resistance - Antibiotics 2024 (UK)
- Developing Alternatives to Antibiotics - Antibiotics 2024 (UK)
- Drug Discovery and Novel Delivery Technologies - Antibiotics 2024 (UK)
- Immune System - IMMUNOLOGY 2024 (Spain)
- Immuno informatics & Systems immunology - IMMUNOLOGY 2024 (Spain)
- Immuno-Genetics - IMMUNOLOGY 2024 (Spain)
- Immunogenetics - IMMUNOLOGY 2024 (Spain)
- Immunohistochemistry - IMMUNOLOGY 2024 (Spain)
- Immunology - IMMUNOLOGY 2024 (Spain)
- Immunology & Vaccines - Antibiotics 2024 (UK)
- Immunotherapy - IMMUNOLOGY 2024 (Spain)
- Infectious Diseases - Antibiotics 2024 (UK)
- Mechanism and Evolution of Antibiotic Resistance - Antibiotics 2024 (UK)
- Micro Organisms in Recent Drug Discovery - Antibiotics 2024 (UK)
- Microorganisms Producing Antibiotics - Antibiotics 2024 (UK)
- Modern Antibiotics for Various Diseases and Infections - Antibiotics 2024 (UK)
- New antibiotics and non-antibiotic approaches - Antibiotics 2024 (UK)
- Nutritional Immunology - IMMUNOLOGY 2024 (Spain)
- OncoImmunology - IMMUNOLOGY 2024 (Spain)
- Pediatric and Neonatal Immunology - IMMUNOLOGY 2024 (Spain)
- Pharmacokinetics and Pharmacodynamics of Antimicrobial Drugs - Antibiotics 2024 (UK)
- Pharmacology & Toxicology - Antibiotics 2024 (UK)
- Prevention and Control of Antibiotic Resistance - Antibiotics 2024 (UK)
- Reproductive Immunology - IMMUNOLOGY 2024 (Spain)
- The Next Generation Approach of Antibiotics - Antibiotics 2024 (UK)
- Transplantation and Computational Immunology - IMMUNOLOGY 2024 (Spain)
- Vaccines & Immunization - IMMUNOLOGY 2024 (Spain)
- Virology and infectious diseases - IMMUNOLOGY 2024 (Spain)